Michael S.  Poirier net worth and biography

Michael Poirier Biography and Net Worth

Michael S. Poirier founded Qualigen in 1996 and is its Chairman, President and Chief Executive Officer. Prior to founding Qualigen, Mr. Poirier was Vice President of Marketing for Ashirus Technologies, Inc., a Minneapolis-based manufacturer of innovative high-precision dispensing pumps and related equipment for the medical industry. From 1993 to 1995, Mr. Poirier was Director of US Area Operations for EnSys, Inc., located in Research Triangle, North Carolina. EnSys developed and manufactured field-portable immunoassay test kits for the environmental remediation industry. From 1991 to 1993, Mr. Poirier was employed by Sanofi Pasteur in Chaska, Minnesota, as a Marketing Manager responsible for launching the ACCESS® Immunoassay System. This novel diagnostic system was later acquired by Beckman-Coulter and is now one of the leading immunoassay test systems worldwide. From 1985 to 1991, Mr. Poirier was employed by Abbott Diagnostics, a division of Abbott Laboratories, Inc. in various marketing and sales positions, including Worldwide Immunoassay Product Manager for the IMx® and AxSym® immunoassay diagnostic systems. Both IMx and later, AxSym, became the leaders in their respective markets. Prior to working at Abbott, Mr. Poirier served as an officer in the United States Navy, assigned to the US Atlantic Fleet. Mr. Poirier holds a B.A. from Providence College and attended the University of Zürich, Switzerland, School of Law.

What is Michael S. Poirier's net worth?

The estimated net worth of Michael S. Poirier is at least $15,537.60 as of June 22nd, 2022. Mr. Poirier owns 3,984 shares of Qualigen Therapeutics stock worth more than $15,538 as of December 22nd. This net worth evaluation does not reflect any other investments that Mr. Poirier may own. Additionally, Mr. Poirier receives a salary of $632,700.00 as CEO at Qualigen Therapeutics. Learn More about Michael S. Poirier's net worth.

How old is Michael S. Poirier?

Mr. Poirier is currently 68 years old. There are 1 older executives and no younger executives at Qualigen Therapeutics. Learn More on Michael S. Poirier's age.

What is Michael S. Poirier's salary?

As the CEO of Qualigen Therapeutics, Inc., Mr. Poirier earns $632,700.00 per year. Learn More on Michael S. Poirier's salary.

How do I contact Michael S. Poirier?

The corporate mailing address for Mr. Poirier and other Qualigen Therapeutics executives is 2042 Corte Del Nogal, Carlsbad CA, 92011. Qualigen Therapeutics can also be reached via phone at (760) 918-9165 and via email at [email protected]. Learn More on Michael S. Poirier's contact information.

Has Michael S. Poirier been buying or selling shares of Qualigen Therapeutics?

Michael S. Poirier has not been actively trading shares of Qualigen Therapeutics during the last quarter. Most recently, on Wednesday, June 22nd, Michael S. Poirier bought 600 shares of Qualigen Therapeutics stock. The stock was acquired at an average cost of $28.50 per share, with a total value of $17,100.00. Following the completion of the transaction, the chief executive officer now directly owns 3,984 shares of the company's stock, valued at $113,544. Learn More on Michael S. Poirier's trading history.

Who are Qualigen Therapeutics' active insiders?

Qualigen Therapeutics' insider roster includes Amy Broidrick (EVP), Kurt Kruger (Director), and Michael Poirier (CEO). Learn More on Qualigen Therapeutics' active insiders.

Michael S. Poirier Insider Trading History at Qualigen Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/22/2022Buy600$28.50$17,100.003,984View SEC Filing Icon  
4/20/2021Buy220$90.00$19,800.003,384View SEC Filing Icon  
See Full Table

Michael S. Poirier Buying and Selling Activity at Qualigen Therapeutics

This chart shows Michael S Poirier's buying and selling at Qualigen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Qualigen Therapeutics Company Overview

Qualigen Therapeutics logo
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Read More

Today's Range

Now: $3.90
Low: $3.90
High: $4.16

50 Day Range

MA: $5.13
Low: $3.60
High: $9.13

2 Week Range

Now: $3.90
Low: $3.34
High: $30.50

Volume

30,713 shs

Average Volume

90,137 shs

Market Capitalization

$2.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A